Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Juan Francisco Marín Pozo"'
Autor:
Raquel Claramunt García, Carmen Lucía Muñoz Cid, Juan Francisco Marín Pozo, Andres Sanchez Ruiz
Publikováno v:
European Journal of Clinical Pharmacology. 78:287-291
To evaluate and compare the efficacy and safety of bevacizumab and aflibercept in second-line treatment in metastatic colorectal cancer (mCRC) in real-life clinical practice.Retrospective observational study of patients treated with second-line bevac
Autor:
Beatriz Mora Rodríguez, María Carmen Martínez Díaz, Juan Francisco Marín Pozo, Begoña Muros de Fuentes, Paz Quesada Sanz, Fátima Artime Rodríguez-Hermida, María José Martínez Bautista, Úrsula Baños Roldán, José Carlos Roldán Morales, Patricia Rodríguez Gómez, María Teresa Garrido Martínez, Ana I. Sánchez, Juan Manuel Duarte Pérez, Macarena Merino Almazán, Rosa Villatoro Roldán, Antonio Rueda Ramos, Ángel Inoriza Rueda, José Miguel García, Margarita Garrido Siles, Pablo Nieto Guindo, Ana Laura Ortega Granados, Silvia Maria Artacho Criado
Publikováno v:
International Journal of Clinical Pharmacy. 41:272-279
Background Immunotherapy has become a standard treatment for lung cancer; however, the high cost makes it necessary to assess health outcomes. Objective The aim of this study was to evaluate the effectiveness, safety and economic cost of nivolumab in
Autor:
Pedro Sánchez-Rovira, Carmen Herrero-Rodríguez, Leticia Díaz-Beltrán, Celia Lacárcel-Bautista, María Ángeles Duro-Fernández, Manuel Ruiz-Bailén, Juan Francisco Marín-Pozo, Ana Laura Ortega Granados, Luis Yaguez-Mateos, Gaspar Jesús Duro-Ruiz, Javier García-Alegría, Gerardo Pérez-Chica, Francisco García-Verdejo, Maria Isabel Sierra-Torres, Mónica Fernández-Navarro, Josefa A. Aguilar-García, Natalia Luque-Caro, Agustín Rodríguez-Sánchez, Fernando Gálvez-Montosa, Cristina Quero-Blanco
Publikováno v:
SSRN Electronic Journal.
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a subgroup of patients with severe symptomatology might have cytokine storms, wh
Autor:
Leticia Díaz-Beltrán, Manuel Ruiz-Bailén, Luis Yaguez-Mateos, María Ángeles Duro-Fernández, Pedro Sánchez-Rovira, Mónica Fernández-Navarro, Ana Laura Ortega-Granados, Juan Francisco Marín-Pozo, Carmen Herrero-Rodríguez, J. García-Alegría, Josefa A. Aguilar-García, Francisco García-Verdejo, Natalia Luque-Caro, Gerardo Pérez-Chica, Celia Lacárcel-Bautista, Fernando Gálvez-Montosa, Cristina Quero-Blanco, Agustín Rodríguez-Sánchez, Maria Isabel Sierra-Torres, Gaspar Jesús Duro-Ruiz
Publikováno v:
Medicine
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a subgroup of patients with severe symptomatology might have cytokine storms, which increase
Publikováno v:
Digibug. Repositorio Institucional de la Universidad de Granada
instname
Medicine
instname
Medicine
To evaluate the safety and efficacy of bevacizumab in a broader patient population with solid tumors in the context of general clinical practice. Moreover, we quantified the economic impact and characterized the off-label use (OLU) of this agent in r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccf226dd26d2ea0909ff74beb2dbabb
http://hdl.handle.net/10481/44560
http://hdl.handle.net/10481/44560
Autor:
Miguel Angel Moreno Jimenez, Mónica Fernández Navarro, Carmen Garrido, Ana Laura Ortega Granados, Juan Francisco Marín Pozo, Nuria Cárdenas Quesada, Pedro Sánchez Rovira, Francisco José García Verdejo, Natalia Luque Caro, Capilla de la Torre Cabrera, María Ruiz Sanjuan
Publikováno v:
Journal of Thoracic Oncology. 12:S917-S918
Autor:
Francisco José García Verdejo, David Fernández Garay, Mónica Fernández Navarro, Ana Laura Ortega Granados, Pedro Sánchez Rovira, Juan Francisco Marín Pozo, Nuria Cárdenas Quesada, Miguel Angel Moreno Jimenez, Capilla de la Torre Cabrera, María Ruiz Sanjuan, Carmen Garrido, Natalia Luque Caro
Publikováno v:
Journal of Thoracic Oncology. 12:S700-S701
Autor:
Capilla de la Torre Cabrera, Ana Laura Ortega Granados, Juan Francisco Marín Pozo, Nuria Cárdenas Quesada, Carmen Tirado Bejarano, Mónica Fernández Navarro, Natalia Luque Caro, Francisco José García Verdejo, Facundo Alberti Vargas, Miguel Angel Moreno Jimenez, María Ruiz Sanjuan, Pedro Sánchez Rovira
Publikováno v:
Journal of Clinical Oncology. 36:e18032-e18032
e18032Background: All patients diagnosed of advanced or relapsed squamous cell carcinoma of head and neck (SCCHN) are relapsing before a platin-based first line therapy, and then, median overall su...
Autor:
María Teresa Garrido Martínez, Juan Francisco Marín Pozo, Carmen Martínez Díaz, Juan Manuel Duarte Pérez, José Carlos Roldán Morales, Margarita Garrido Siles, Ana I. Sánchez, Facundo Alberti Vargas, María José Martínez Bautista, Begoña Muros de Fuentes, María Dolores Alvarado Fernández, Pablo Nieto Guindo, Pedro Sánchez Rovira, Beatriz Mora Rodríguez, Silvia Maria Artacho Criado, Macarena Merino Almazán, Fátima Artime-Rodríguez-Hermida, María Paz Quesada Sanz
Publikováno v:
Journal of Clinical Oncology. 36:e21092-e21092
e21092Background: Nivolumab is recommended as a standard-of-care treatment in patients (pts) with progression to first-line therapy for non-smal-cell lung cancer (NSCLC). Our objective is to evalua...
Autor:
Victor Navarro Pérez, Natalia Luque Caro, David Fernández Garay, María Ruiz Sanjuan, Miguel Angel Moreno Jimenez, Pedro López Leiva, Ana Laura Ortega Granados, Capilla de la Torre Cabrera, Maria Carmen Álamo de la Gala, Rosario Dueñas García, Esther Martínez Ortega, Francisco José García Verdejo, Yessica Plata Fernández, Juan Francisco Marín Pozo, Nuria Cárdenas Quesada, Rosa Millán García, Mónica Fernández Navarro, Ana Jaén Morago, Maria Lomas Garrido, Pedro Sánchez Rovira
Publikováno v:
Journal of Clinical Oncology. 35:e20515-e20515
e20515 Background: It is known that outcome of patients included in clinical trials have a better outcome than patients treated with standard therapy. This is a retrospective case-control study of outcome of patients with stage III and IV non-small c